Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisporivir Triple Therapy in Treatment-Naïve HCV Genotype 1
NCT01318694Phase 3Completed
- Sponsor
- Debiopharm
- Start
- Mar 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of alisporivir in hepatitis C (HCV) (4 arms), sponsored by Debiopharm. Primary endpoint: Sustained Virologic Response 12 Weeks After End of Treatment. Started Mar 2011; status: completed.
02
Drugs
alisporivir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01318694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01318694.